Skip to content

NASDAQ · small · thesis board

AVXL Anavex Life Sciences

Sigma-1 receptor agonist (blarcamesine)

View race

Thesis

Editorial summary — not a primary filing

Sigma-1 agonist blarcamesine pursuing Alzheimer path with regulatory uncertainty still elevated.

Next gate

2026-12-15EstimatedNDA BLA filing

Regulatory filing decision

124 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~11 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~456d)100%
Days to gate (124d)27%
Show math

$120M cash ÷ $8M/mo burn ≈ 456 days. Source: curated SEC quarter figures.

Cash $120M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
LLYApprovedokBIIBApprovedokANVSPh3ok

Risks

  • Regulatory skepticism
  • Endpoint interpretation
  • Financing needs
  • Competitive Alzheimer bar

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT03790709as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01